Skip to main content

Advertisement

Table 1 Odds ratio (95 % CI) by direct comparison (left lower part) and network meta- analysis (right upper part) based on ACR20

From: Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis

TwHF 15.56 (1.63–148.5) 12.09 (1.31–111.5) 11.76 (1.21–113.9) 0.89 (0.00–2.18e+28) 14.77 (1.59–137.2) 17.04 (1.76–165.3) 33.33 (4.17–100.0)
1.49 (0.73–3.08) MTX 0.78 (0.43–1.41) 0.76 (0.35–1.61) 0.06 (0.00–1.35e+27) 0.95 (0.51–1.76) 1.10 (0.51–2.34) 2.38 (1.45–4.00)
0.94 (0.79–1.10) LEF 0.97 (0.51–1.86) 0.07 (0.00–1.74e+27) 1.22 (0.76–1.97) 1.41 (0.74–2.70) 3.13 (2.27–4.17)
3.81(1.79–8.09) 0.89 (0.57–1.39) 1.25 (0.97–1.61) SSZ 0.08 (0.00–1.79e+27) 1.26 (0.64–2.46) 1.45 (0.65–3.24) 3.23 (1.82–5.56)
0.47 (0.15–1.46) CsA 16.52 (0.00–3.88e+29) 19.06 (0.00–4.48e+29) 50.00 (0.00–100.0)
FK506 1.15 (0.59–2.26) 2.56 (1.75–3.70)
MINO 2.22 (1.25–3.85)
36.77 (1.91–708.0) 2.41 (1.46–3.98) 3.03 (2.21–4.14) 3.18 (1.80–5.62) 2.38 (1.69–3.76) 2.19 (1.25–3.88) Placebo
  1. Results of direct comparisons are listed in the lower-left triangle, and the estimation is calculated as the row-defining treatment compared with the column-defining treatment. Results of network meta-analysis are listed in the upper-right triangle, and the estimation is calculated as the column-defining treatment compared with the row-defining treatment
  2. TwHF Tripterygium wilfordii Hook F, MTX methotrexate, LEF leflunomide, SSZ sulphasalazine, CsA cyclosporine, FK506 tacrolimus, MINO minocycline